Monday, November 23, 2009, 8:46pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

CombinatoRx, Incorporated (CRXX)

 At 16:00 EST: 1.12 USD  Up 0.05 (4.67%)  
MORE ON CRXX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
CombinatoRx, Incorporated (NGM:CRXX) Delayed quote dataEdit
After Hours: 1.18 Up 0.06 (5.36%) as of 4:23pm EST on 11/23/09
Last Trade: 1.12 USD
Trade Time: 4:00PM EST
Change: Up 0.05 (4.67%)
Prev Close: 1.07
Open: 1.19
Bid: N/A
Ask: 2.00 x 1100
1y Target Est: 1.00
Day's Range: 1.09 - 1.20
52wk Range: 0.25 - 2.60
Volume: 991,416
Avg Vol (3m): 879,123
Market Cap: 39.24M
P/E (ttm): N/A
EPS (ttm): -0.72
Div & Yield: N/A (N/A%)
CombinatoRx, Incorporated (CRXX)
1d  5d  3m  6m  1y  2y  5y 
 Add CRXX to Portfolio   Download Data

HEADLINES
• COMBINATORX, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 20)
• FDA Extends NDA Review for Exalgo Extended-Release Tablets
Business Wire (Fri, Nov 20)
• BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
at Seeking Alpha (Tue, Nov 17)
• CombinatoRx Shares Fall as Neuromed Drug Not Approved by FDA
at Fox Business (Mon, Nov 16)
• Sprint, CombinatoRx: Early Volume Plays
at TheStreet.com (Mon, Nov 16)
• UPDATE - CombinatoRx: Neuromed pain drug may not get approval
at Reuters (Mon, Nov 16)
• COMBINATORX, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Mon, Nov 16)
• Neuromed Receives FDA Feedback on New Drug Application for Exalgo Extended-Release Tablets
Business Wire (Mon, Nov 16)
• COMBINATORX, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibit
EDGAR Online (Tue, Nov 10)
• COMBINATORX, INC Financials
EDGAR Online Financials (Sat, Nov 7)
• CombinatoRx narrows loss on deep R&D cuts
at bizjournals.com (Tue, Nov 3)
More Headlines for CRXX...
ANALYST
EPS Est (next year) (Dec-09) : N/A
EPS Est (in 2 years) (Dec-10) : N/A
Avg Rec (current)*: 3.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combina...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices